一个程序的可靠性,以细分由帕金森病的演讲者产生的即兴演讲
Anna Gravelin Coy1, Brent Archer2, Mary Oddo2
1Division of Communication Sciences and Disorders, West Virginia University, Morgantown, West Virginia, USA.
Clinical linguistics & phonetics
|September 24, 2025
概括
这项研究验证了系统功能语言学 (SFL) 对帕金森病 (PD) 患者的语音细分方法. 该SFL方法可靠地分割语音,使得语音和PD中的口音能够进行声学分析.
科学领域:
- 语言学的语言学.
- 语音科学 语言科学
- 神经学 神经学
背景情况:
- 随机语音分析对于理解沟通障碍至关重要.
- 系统功能语言学 (SFL) 为语音细分提供了一个框架.
- 之前的SFL细分方法需要对特定临床群体进行验证.
研究的目的:
- 对患有帕金森病 (PD) 的人进行基于SFL的语音细分程序的可靠性和实用性进行评估.
- 调查SFL细分在分析PD语音声学属性的应用.
主要方法:
- 十名患有帕金森病 (PD) 的参与者制作了语音样本.
- 两名专家和一名临床分析师应用了基于SFL的细分程序来识别条款和条款复合体.
- 计算了评审者内部和评审者间的可靠性.
- 对每个复杂句子进行了声学测量 (持续时间,暂停时间,语音速度).
主要成果:
- 在PD扬声器中观察到SFL细分的高intra-和inter-rater可靠性 (κ = 0.661-0.855,p < 0.001).
- 声学分析显示,在扬声器内和扬声器之间,音节生成和持续时间的预期变化.
- 在患有PD的个体中,SFL方法被证明是可靠的语音细分方法.
结论:
- 基于SFL的句子集中细分方法是分析帕金森病 (PD) 患者即兴言语的可靠方法.
- 这种细分技术有助于在PD中声学检查语音和口音.
- 经过验证的方法支持进一步研究与PD相关的沟通变化.
相关概念视频
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


